Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start [Seeking Alpha]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Seeking Alpha
The company demonstrated 60% mean microdystrophin expression at Day 90 in its phase 1/2 INSPIRE DUCHENNE trial, with safety confirmed in 40 patients. A $240 million private placement in March 2026 extends the cash runway, supporting key milestones through 2027. Upcoming catalysts include phase 3 IMPACT DUCHENNE first dosing in Q1 2026 and a potential FDA Accelerated Approval update by mid-2026. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Nacer HA/iStock via Getty Images The last time I spoke about Solid Biosciences SLDB ), it was in a Seeking Alpha article entitled " Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones ." With respect More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.MarketBeat
- Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.MarketBeat
- Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.MarketBeat
- Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences GAAP EPS of -$0.53 misses by $0.02 [Seeking Alpha]Seeking Alpha
SLDB
Earnings
- 3/19/26 - Miss
SLDB
Sec Filings
- 3/19/26 - Form S-3
- 3/19/26 - Form S-3
- 3/19/26 - Form S-8
- SLDB's page on the SEC website